Vertex Pharmaceuticals
VRTX
1,765 hedge funds and large institutions have $120B invested in Vertex Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 194 funds opening new positions, 708 increasing their positions, 623 reducing their positions, and 111 closing their positions.
75% more first-time investments, than exits
New positions opened: 194 | Existing positions closed: 111
57% more capital inflows, than outflows
Capital inflows: $7.18B | Capital outflows: $4.58B
14% more repeat investments, than reductions
Existing positions increased: 708 | Existing positions reduced: 623
4% more funds holding
Funds holding: 1,701 → 1,765 (+64)
1.54% more ownership
Funds ownership: 93.6% → 95.14% (+1.5%)
9% more call options, than puts
Call options by funds: $853M | Put options by funds: $783M
29% less funds holding in top 10
Funds holding in top 10: 17 → 12 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.24B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$331M |
| 3 |
SG Americas Securities
New York
|
+$207M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$197M |
| 5 |
Millennium Management
New York
|
+$194M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$725M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$395M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$250M |
| 4 |
JP Morgan Chase
New York
|
-$228M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$191M |
VRTX Hedge Fund Activity: Q2 2026 in Review
1,765 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2026, worth a combined $120B — up 13% from $106B a quarter earlier.
Buyers outnumbered sellers: 194 funds opened new VRTX positions and 111 closed out — a net gain of 83 holders — while 708 added to existing stakes and 623 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.24B. The largest seller was Capital Research Global Investors, cutting an estimated $725M.
- 1,765 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2026, up from 1,701 in Q1 2026.
- Funds reported $120B of Vertex Pharmaceuticals stock for Q2 2026, up 13% quarter-over-quarter.
- 194 funds opened new Vertex Pharmaceuticals positions in Q2 2026 and 111 closed out, a net change of +83 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2026 was Franklin Resources, an estimated $1.24B added.
- The largest Vertex Pharmaceuticals seller in Q2 2026 was Capital Research Global Investors, an estimated $725M sold.
Based on aggregated 13F filings for Q2 2026.